Restless leg syndrome. Restless legs syndrome
Conditions
Interventions
Intervention 1: Intervention group: In the melatonin group, one 3 mg melatonin tablet produced by Razak company will be prescribed daily for 2 months for each patient. Intervention 2: Control group: I
Sponsors
Arak University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: All patients with restless leg syndrome who visited Amir al-Momenin Arak Hospital. Aged 18-65 years old A history of illness for at least three months Consent to participate in the study
Exclusion criteria
Exclusion criteria: The presence of an underlying neurological disorder Having a history of spinal cord injury disorders or cerebral sensory and motor disorders The presence of chronic kidney and liver disease through the tests of patients in the file, which are evaluated in terms of routine liver and kidney tests at the beginning of the visit. pregnancy Taking drugs that interfere with melatonin, such as anti-epileptic drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity of the disease. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: International Restless Legs Syndrome questionnaire.;Sleep quality score. Timepoint: Before the intervention and 8 weeks after the intervention. Method of measurement: Pittsburgh Sleep Questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Alireza Rezaei Ashtiani
Arak University of Medical Sciences
Outcome results
None listed